MaxCyte Inc
LSE:MXCT
MaxCyte Inc
Operating Income
MaxCyte Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MaxCyte Inc
LSE:MXCT
|
Operating Income
-$48.3m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Operating Income
$7.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
Danaher Corp
NYSE:DHR
|
Operating Income
$9.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Operating Income
$1.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
Agilent Technologies Inc
NYSE:A
|
Operating Income
$1.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Operating Income
$2.1B
|
CAGR 3-Years
38%
|
CAGR 5-Years
21%
|
CAGR 10-Years
16%
|
See Also
What is MaxCyte Inc's Operating Income?
Operating Income
-48.3m
USD
Based on the financial report for Dec 31, 2023, MaxCyte Inc's Operating Income amounts to -48.3m USD.
What is MaxCyte Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-42%
Over the last year, the Operating Income growth was -77%. The average annual Operating Income growth rates for MaxCyte Inc have been -63% over the past three years , -42% over the past five years .